Zanubrutinib as a salvage therapy for ibrutinib-resistant chronic lymphocytic leukemia: a case report
The findings from this case report suggest that zanubrutinib may provide a viable treatment option for patients with CLL/SLL who have progressed on ibrutinib. Further studies and clinical trials are warranted to confirm these observations and to explore the broader applicability of zanubrutinib in managing ibrutinib-resistant CLL/SLL.
Authors
- Changhua Jing
- Zhenhui Lv
- Xueqiong Wu (ORCID: https://orcid.org/0000-0002-0744-9420)
- Ping Lü (ORCID: https://orcid.org/0000-0002-0127-3911)
- X. Yi (ORCID: https://orcid.org/0000-0003-1260-1367)
Institutions
- Central Hospital of Zibo (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-09-25
- DOI
- https://doi.org/10.3389/fonc.2025.1671124
- Primary Topic
- Chronic Lymphocytic Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00